Drugs / SAM-315
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00474552 | Jun → Oct 2007 | Alzheimer disease | Wyeth is now a wholly owned subsidiary of Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT00480467 | Sep 2006 → Aug 2007 | Alzheimer disease | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00479440 | Aug 2006 → Mar 2007 | Alzheimer disease | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAM-315 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00479440 ↗ |
| Route | Oral | “multiple oral doses of SAM-315” NCT00474552 ↗ |